Pokhrel NK, et al. - Data were assessed by authors to estimate the impact of Bruton's tyrosine kinase inhibitor acalabrutinib on osteoclast differentiation and P. gingivalis lipopolysaccharide-induced alveolar bone resorption. They observed inhibition of receptor activator of nuclear factor κB ligand (RANKL) and LPS-induced in vitro osteoclast differentiation with acalabrutinib employment. They noticed suppression of Ca²⁺ oscillation in osteoclast precursors following a decline in NFATc1 expression and nuclear localization (essential for osteoclastogenesis). A notable reduction in P. gingivalis lipopolysaccharide-induced alveolar bone erosion was recorded in mice after acalabrutinib administration.